Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $283.35M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.53B 139M Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Xencor USD 73.46M 22.45M Mar/2026